HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benn, P. A. Articles by Collins, R. Search for Related Content PubMed PubMed Citation Articles by Benn, P. A. Articles by Collins, R.

Incorporation of Inhibin-A in Second-Trimester Screening for Down Syndrome

From the Division of Human Genetics, Department of Pediatrics, University of Connecticut Health Center, Farmington; and Division of Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, St. Francis Hospital and Medical Center, Hartford, Connecticut.

Address reprint requests to: Peter A. Benn, PhD, Division of Human Genetics, Department of Pediatrics, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-6140; E-mail: benn{at}nso1.uchc.edu.

OBJECTIVE: To evaluate the efficacy of the second-trimester quadruple test (maternal serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin, and inhibin-A) in prenatal screening for Down syndrome.

METHODS: All quadruple tests performed on singleton pregnancies over a 32-month period were reviewed. The sensitivity and false-positive rates were compared with the theoretic rates predicted by the screening model when applied to a population of women with the same maternal age distribution.

RESULTS: Twenty-three thousand seven hundred four women with unaffected pregnancies and 45 women with Down syndrome–affected pregnancies received the quadruple test. Mean analyte values for both unaffected and affected pregnancies were similar to those expected. The sensitivity of the quadruple test, which was based on ascertainment of all viable affected pregnancies in the screened population, was 85.8%. This sensitivity did not significantly differ from an expected 83.8% (P = .8). The initial false-positive rate, 9.0%, was significantly below that expected (9.9%) (P = .002) and was further reduced to 8.2% after correction for major gestational age errors. The positive predictive value of the quadruple test was one in 51. Women with an affected pregnancy and a positive test result (true positives) generally had very high risks (median 1:22) relative to women with false-positive results (median risk 1:111).

CONCLUSION: The quadruple test meets or exceeds performance expectations and appears to represent an improvement over the widely used triple test.

This article has been cited by other articles:

				F. M. Breathnach, F. D. Malone, G. Lambert-Messerlian, H. S. Cuckle, T. F. Porter, D. A. Nyberg, C. H. Comstock, G. R. Saade, R. L. Berkowitz, S. Klugman, et al. First- and Second-Trimester Screening: Detection of Aneuploidies Other Than Down Syndrome Obstet. Gynecol., September 1, 2007; 110(3): 651 - 657. [Abstract] [Full Text] [PDF]

				P. A. Benn, G. S. Makowski, J. F.X. Egan, and D. Wright Reproducibility of Risk Figures in 2nd-Trimester Maternal Serum Screening for Down Syndrome: Comparison of 2 Laboratories Clin. Chem., November 1, 2006; 52(11): 2087 - 2094. [Abstract] [Full Text] [PDF]

				P. A. Benn, J. F. X. Egan, M. Fang, and R. Smith-Bindman Changes in the Utilization of Prenatal Diagnosis Obstet. Gynecol., June 1, 2004; 103(6): 1255 - 1260. [Abstract] [Full Text] [PDF]

				T. W. Hallahan, D. A. Krantz, J. N. Macri, P. Benn, M. Fang, and J. F. X. Egan Incorporation of Inhibin-A in Second-Trimester Screening for Down Syndrome Obstet. Gynecol., August 1, 2003; 102(2): 413 - 414. [Full Text] [PDF]